Ustekinumab

Ustekinumab is a monoclonal antibody used to treat autoimmune disorders. It works by targeting and inhibiting interleukin-12 and interleukin-23, two cytokines involved in the immune system's response.

Indications

Ustekinumab is indicated for the treatment of: -Moderate to severe plaque psoriasis -Active psoriatic arthritis -Moderately to severely active Crohn's disease -Moderate to severe ulcerative colitis

Dosage

Dosage of ustekinumab varies depending on the condition being treated and the patient's weight. It is usually administered by subcutaneous injection or intravenous infusion. A typical dosing schedule may be an initial dose, followed by maintenance doses at specified intervals (e.g., every 8-12 weeks). Always follow the prescribed dosing instructions from a healthcare provider.

Contra-Indications

Ustekinumab should not be used in patients who: -Have a known hypersensitivity to ustekinumab or its excipients

Special Precautions

-Use with caution in patients with active infections or a history of recurrent infections. -Monitor patients for signs and symptoms of infection during treatment. -May increase the risk of malignancies. -Caution in patients with tuberculosis or who are at high risk for TB infection. -Live vaccines should be avoided during treatment.

Side Effects

-Common side effects: upper respiratory tract infections, headache, and fatigue. -Less common but serious side effects: serious infections, malignancies, and allergic reactions.

Drug Interactions

-Ustekinumab may interact with other immunosuppressive agents, increasing the risk of infection. -Live vaccines should not be given concurrently with ustekinumab.